Abstract: Small molecules comprised of azacyclic constrained analogs of FTY720 are provided. Formulations and medicaments are also provided that are directed to the treatment of disease, such as, for example, leukemia, and other diseases. Therapeutics are also provided containing a therapeutically effective dose of one or more small molecule compounds, present either as pharmaceutically effective salt or in pure form, including, but not limited to, formulations for oral, intravenous, or intramuscular administration.
Type:
Grant
Filed:
July 15, 2014
Date of Patent:
September 18, 2018
Assignees:
The Regents of the University of California, The Université de Montréal
Abstract: The invention relates to the field of medicine and concerns an agent that stimulates tissue regeneration and the recovery of diminished tissue and organ function. A medicinal agent for the treatment and/or prophylaxis of a pathological condition selected from the group including metabolic syndrome, impaired glucose tolerance, hepatitis, particularly chronic hepatitis and toxic hepatitis, idiopathic pulmonary fibrosis (IPF), emphysema of the lungs, chronic obstructive pulmonary disease (COPD) and cachexia, particularly as a result of impaired glucose tolerance, pulmonary fibrosis, chronic obstructive pulmonary disease, cancer and other diseases, is proposed in the form of an agent based on Treamide. The latter is a bisamide derivative of dicarboxylic acid of formula (I) or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
May 26, 2016
Date of Patent:
September 18, 2018
Assignee:
Treamid Therapeutics GmbH
Inventors:
Vladimir Evgenievich Nebolsin, Anastasia Vladimirovna Rydlovskaya, Alexandr Mikhailovich Dygai, Tatiana Gennadievna Borovskaya, Evgenii Germanovich Skurikhin
Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
Type:
Grant
Filed:
May 25, 2016
Date of Patent:
August 21, 2018
Assignee:
Genentech, Inc.
Inventors:
Sharada Labadie, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Birong Zhang, Nicholas D. Smith, Steven P. Govek, Mehmet Kahraman, Andiliy G. Lai, Johnny Y. Nagasawa, Simon Charles Goodacre, Nicholas Charles Ray
Inventors:
Dominique Amans, Stephen John Atkinson, Lee Andrew Harrison, David Jonathan Hirst, Robert Peter Law, Matthew Lindon, Alexander Preston, Jonathan Thomas Seal, Christopher Roland Wellaway
Abstract: The present invention relates to certain pyrazole derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor and their uses for the treatment of REM sleep behavior disorder.
Type:
Grant
Filed:
June 10, 2016
Date of Patent:
July 17, 2018
Assignee:
Axovant Sciences GmbH
Inventors:
Lawrence Tim Friedhoff, Shankar Ramaswamy, Yandong Wen
Abstract: A sticker adjuvant that may be used in agrochemical compositions is disclosed. The sticker adjuvant is a polyether amide or a polyether imide formed by the reaction of a polyether polyamine with a polyfunctional monomer. The polyfunctional monomer may be a polyacid, a di-functional acyl halide, an acid anhydride, a poly(acid anhydride) and a mixture thereof.
Type:
Grant
Filed:
December 8, 2016
Date of Patent:
July 10, 2018
Assignee:
HUNTSMAN PETROCHEMICAL LLC
Inventors:
Matthew T. Meredith, Alan J Stern, Dilek Saylik
Abstract: The present invention relates to water treatment. In one embodiment there is provided a method of treating an aqueous system to inhibit growth of one or more micro-organisms therein and/or to reduce the number of live micro-organisms therein. The method comprises adding treatment agents to said aqueous system and wherein said treatment agents comprise: (a) a phosphonium compound; and (b) an oxazolidine compound.
Abstract: A composition suitable for treating a variety of medical, aesthetic and cosmetic conditions in mucous membranes and occluded skin areas, comprising hyaluronic acid, N-acetylcysteine, an active agent and set to pH of less than 6, which is characterized by high in vivo stability, is disclosed, as well as uses thereof in temporally extended delivery of active agent to mucous membrane in bodily sites.
Abstract: A process is provided for the making of estetrol starting from a 3-A-oxy-estra-1,3,5(10),15-tetraen-17-one, wherein A is an C1-C5 alkyl group, preferably a methyl group, or a C7-C12 benzylic group, preferably a benzyl group. This process is particularly suitable to industry.
Type:
Grant
Filed:
December 19, 2014
Date of Patent:
June 19, 2018
Assignee:
Donesta Bioscience B.V.
Inventors:
Mark Theodoor Verhaar, Thomas Koch, Erwin Gerardus Jacobus Warmerdam
Abstract: The present invention refers to a compound selected from the group consisting of a lysophospholipid and a lysophospholipid analog for use in the treatment or prophylaxis of honeybee brood diseases, in particular American foulbrood and European foulbrood. The invention also refers to a diet composition, a sprayable composition, a dipping solution for brood combs, a beeswax composition and liposomal and microsphere- or nanosphere-based compositions, comprising a compound according to the invention, for use in the treatment or prophylaxis of bee brood diseases.
Type:
Grant
Filed:
May 22, 2014
Date of Patent:
June 12, 2018
Assignee:
University of Graz
Inventors:
Wolfgang Schühly, Ulrike Riessberger-Gallé, Javier Hernández-López, Karl Crailsheim
Abstract: The present disclosure relates generally to systems, methods, and compounds for therapeutic use against parasitic infections. More particularly, the disclosure relates to anti-parasitic compounds, and methods for making and for using the anti-parasitic compounds, where the anti-parasitic compounds have the general formula: where X, R1, R2, R3, R4, R5, and R6 are defined more fully below.
Type:
Grant
Filed:
June 14, 2017
Date of Patent:
June 5, 2018
Assignee:
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Abstract: The present invention relates to novel acid-free quaternized nitrogen compounds, to the preparation thereof and to the use thereof as a fuel and lubricant additive, more particularly as a detergent additive, as a wax antisettling additive (WASA) or as an additive for reducing internal diesel injector deposits (IDID); to additive packages which comprise these compounds; and to fuels and lubricants thus additized. The present invention further relates to the use of these acid-free quaternized nitrogen compounds as a fuel additive for reducing or preventing deposits in the injection systems of direct-injection diesel engines, especially in common-rail injection systems, for reducing the fuel consumption of direct-injection diesel engines, especially of diesel engines with common-rail injection systems, and for minimizing power loss in direct-injection diesel engines, especially in diesel engines with common-rail injection systems.
Type:
Grant
Filed:
February 2, 2017
Date of Patent:
June 5, 2018
Assignee:
BASF SE
Inventors:
Wolfgang Grabarse, Harald Boehnke, Christian Tock, Cornelia Roeger-Goepfert, Ludwig Voelkel
Abstract: Compositions and methods for reducing the level of prions in a prion-infected cells or host by exposing prion infected cells, tissues and organs to AR-12 and the AR-12 analog AR-14 to reduce the prion level by at least about 90%.
Type:
Grant
Filed:
February 28, 2017
Date of Patent:
May 22, 2018
Assignees:
OHIO STATE INNOVATION FOUNDATION, UTI LIMITED PARTNERSHIP
Inventors:
Hermann M. Schaetzl, Basant Abdulrahman, Sabine Gilch, Alexander Zukiwski, Stefan Proniuk
Abstract: The process relates improving terephthalic acid purge filtration rate by controlling % water in filter feed slurry and to the recovery of a metal catalyst from an oxidizer purge stream produced in the synthesis of carboxylic acid, typically terephthalic acid, while utilizing pressure filtration.
Type:
Grant
Filed:
August 20, 2010
Date of Patent:
May 8, 2018
Assignee:
Grupo Petrotemex, S.A. de C.V.
Inventors:
Kenny Randolph Parker, Larry Wayne Blair
Abstract: Substituted 4-azaindoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.
Type:
Grant
Filed:
July 8, 2016
Date of Patent:
May 8, 2018
Assignee:
Janssen Pharmaceutica NV
Inventors:
Christa C. Chrovian, Michael A. Letavic, Jason C. Rech, Akinola Soyode-Johnson, Jessica L. Wall
Abstract: A composition comprising caffeoylshikimic acids, protocatechuic acid, hydroxytyrosol, hydroxybenzoic acid, caffeoylshikimic acids and their derivatives extracted from any part of oil palm including but not confined to the vegetation liquor of palm oil milling and palm oil mill effluent, and a method for use in the preparation of a composition containing caffeoylshikimic acids, protocatechuic acid, hydroxytyrosol, hydroxybenzoic acid, caffeoylshikimic acids and their derivatives.
Type:
Grant
Filed:
June 13, 2017
Date of Patent:
May 8, 2018
Assignee:
Malaysian Palm Oil Board
Inventors:
T. G. Sambandan, ChoKyun Rha, Anthony J. Sinskey, Ravigadevi Sambanthamurthi, Yew Ai Tan, Kalyana Sundram P. Manickam, Mohd Basri Wahid
Abstract: The present invention relates to use of a tall oil fatty acid and/or a tall oil fatty acid which is modified by saponification in binding toxins.
Abstract: Disclosed are compounds of general formula A useful as potential anti-tubercular agents.
Type:
Grant
Filed:
March 1, 2016
Date of Patent:
April 24, 2018
Assignee:
COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH
Inventors:
Ahmed Kamal, Rajesh Vcrnc Shetti, Ponnampalli Swapna, Shaik Azeeza, A. Malla Reddy, Inshad Ali Khan, Sheikh Tasduq Abdullah, Sandeep Sharma, Nitin Pal Kalia
Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
Type:
Grant
Filed:
July 8, 2016
Date of Patent:
March 13, 2018
Assignee:
Rigel Pharmaceuticals, Inc.
Inventors:
Rajinder Singh, Ankush Argade, Donald Payan, Susan Molineaux, Sacha Holland, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander Rossi